Biotech Milestone: Aptevo's AML Drug Hits 90% Remission Rate Aptevo Therapeutics has reported groundbreaking results from its RAINIER trial, with 9 out of 10 frontline AML patients achieving remission. The triplet therapy of mipletamig, venetoclax, and azacitidine outperformed standard treatments, achieving a 90% remission rate. This marks a significant advancement in acute myeloid leukemia treatment.12